Abstract
Background: Severe 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency is a heterogeneous metabolic disorder inherited in an autosomal recessive manner. Pathogenic mutations in MTHFR gene have been associated with severe MTHFR deficiency. The clinical presentation of MTHFR deficiency is highly variable and associated with several neurological anomalies.
Methods: Direct whole-exome sequencing (WES) was performed in all the five available individuals from the family, including the affected individual (III-7) using standard procedures.
Results: We observed a proband (III-7) with an abnormality in the cerebral white matter, apnoea, and microcephaly. WES analysis identified a novel homozygous non-sense mutation (c.154C>T; p.Arg52*) in MTHFR gene that segregated with the disease phenotype within the family.
Conclusion: We identified a novel non-sense mutation in MTHFR gene in a single Egyptian family with severe MTHFR deficiency. The present investigation is clinically important, as it adds to the growing list of MTHFR mutations, which might help in genetic counseling of families of affected children and proper genotype-phenotype correlation.
Background
Severe 5,10-Methylenetetrahydrofolate reductase (MTHFR; OMIM 236250) deficiency is a rare inborn error of metabolism and inherited in an autosomal recessive fashion. It is a very common disorder of folate metabolism and is clinically characterized with low plasma methionine level, high homocysteine level, homocystinuria, and hyperhomocysteinemia (1, 2).
MTHFR gene is responsible for the assembly of MTHFR enzyme, which plays a very important role in the catalysis of 5,10-methyltetrahydrofolate (THF) to 5-methyltetrahydrofolate (an NADPH-dependent irreversible reduction) to obtain methionine from homocysteine (Supplementary Figure 1). Methyl THF is the most common form of folate in tissues and the plasma and serves as the methyl group donor in the methyl THF-homocysteine S-methyltransferase reaction involving remethylation of homocysteine to methionine (3).
The deficiency of MTHFR enzyme causes an increase in the concentration of homocysteine and methionine, resulting in severe neurological phenotypes. Patients having neonatal onset (i.e., early onset <1-year-old) MTHFR deficiency are mostly associated with feeding problems, neurological phenotype, microcephaly, seizures, and communicating hydrocephalus, while the late onset is characterized with delayed developmental milestones, cognitive impairment and/or gait abnormalities, stroke, apnoea, paresthesia, psychiatric disturbances, and neurological deterioration, which lead to coma and even death (4, 5).
In the present study, we performed direct whole exome sequencing (WES) to ascertain the genetic cause of severe MTHFR deficiency in the single affected individual (proband). As a result, we identified a homozygous non-sense mutation in MTHFR gene located on chromosome 1p36.22.
Case Presentation
Clinical Examination
The proband (III-7) genetically and clinically analyzed in the present study belongs to a non-consanguineous Egyptian family (Figure 1A). The parents had total seven children, three had deceased (III-1, III-2, and III-3) and showed (i.e., early onset <1 year old) similar phenotypes as the proband, healthy twin daughters (III-4 and III-5), one miscarriage (III-6), and the proband (III-7) (early onset <1 year). The deceased children age were: III-1:40 days, III-2: 2 months, III-3: 45 days; and all the deceased children became lethargic, hypoactive with poor suckling, with associated prolonged sleepiness. These were referred to the neonatal intensive care unit (NICU) as quarry neonatal sepsis. Computed tomography (CT) scan revealed subarachnoid hemorrhage and the patients died of apnoea, disseminated intravascular coagulation (DIC), and cardiorespiratory arrest.
Figure 1
First Clinical Evaluation
During the first clinical investigation, the proband (female; III-7) was 1-month-old with features such as non-obstructive hydrocephalus, recurrent apnea, microcephaly, and white matter abnormality (Figure 1B). The proband showed delayed growth during the last month of gestation. At birth, the head circumference was 31.5 cm, and the birth weight was 2,980 grams (Figure 1B). After 14 days, the proband developed apnea attacks and bradypnea and showed difficulties with swallowing. Ophthalmological examination demonstrated bilateral optic nerve hypoplasia, left retinal multiple hemorrhages, and normal anterior segment. The laboratory screening results revealed low white blood cell count, low platelet count, and high number of lymphocytes. Following multiple episodes of apnea, multi-sequential and multiplanar magnetic resonance imaging (MRI) was performed. The MRI findings showed bilateral abnormal almost symmetrical T2. High signal intensity was observed in the white matter along the bilateral horn deep in the white matter, suggestive of white matter disease (Figure 1C). No chest infection, deafness, or cardiovascular anomaly was noted. The proband had a total blood homocysteine level of 163 nmol/mL (normal, 3.7–12.5 nmol/mL) and the plasma methionine range of < 5 (10–39 μmol/L). The proband was on regular medication such as betaine (100 mg·kg−1·day−1), methionine (50 mg·kg−1·day−1), vitamin B12 (5 mg PO 1/day), and L-5-MTHF (15 mg PO 1/day).
Follow-Up Examination
Follow-up examination after 10 months revealed that the proband could support her head but could not sit without support and may easily roll over (Figure 1D). Ophthalmic examination revealed optic atrophy, retinal hemorrhage, and the affected individual was unable to fix eyes nor follow. No hearing abnormality was observed. The proband was able to make sounds at the age of 4–5 months. Physical examination revealed a height of 79 cm (>95th percentile), weight of 10.7 kg (>95th percentile), and head circumference of 48 cm (>95th percentile). The total blood homocysteine level was 68 nmol/mL (normal, 3.7–12.5 nmol/mL), while the plasma methionine level was 54 μmol/L (normal, 10–39 μmol/L).
Materials and Methods
Study Approval and Sample Collection
The present study was approved by the Institutional Review Board (KAIMRC) and followed Helsinki protocols. Written informed consent was obtained from the parents of the participant for the research study, presentation of photographs/radiographs, and publication of this case report.
DNA Extraction
DNA was extracted from peripheral blood samples using QIAamp DNA Micro kit (Hilden, Germany) and quantified using NanoDropâ„¢ spectrophotometer using standard procedures.
WES
WES was commercially performed (Centogene, Rostock, Germany) for five family members, including the single affected individual (proband: III-7), both parents (II-3 and II-4), and twin sisters (III-4 and III-5) using Illumina platform (Illumina, Inc., San Diego, CA, USA; Figure 1A). RNA capture baits against approximately 60 Mb of the human exome (targeting >99% of regions in the consensus coding sequence, RefSeq, and Gencode databases) were used to enrich the regions of interest from the fragmented genomic DNA with the SureSelect Human All Exon V6 kit (Agilent Technologies, Santa Clara, CA, USA). The generated library was sequenced to obtain an average coverage depth of about 100X. In general, about 97% of the targeted bases are covered in more than 10X. Data analysis and interpretation were performed by Centogene using an end-to-end in-house bioinformatic pipeline with applications including base calling and alignment of reads to the GRCh37/hg19 (GRCh37; http://genome.ucsc.edu/) genome assembly.
Filtering of the Disease-Causing Variants
Primary filtering out of low-quality reads and probable artifacts and the subsequent annotation of variants were performed using standard methods. As the pedigree depicted autosomal recessive inheritance, homozygous and compound heterozygous variants were preferred but heterozygous variants were not ignored.
The variants were filtered and validated using standard methods (6) and screened in different databases such as dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 genomes Project (http://www.internationalgenome.org/), ExAC (http://exac.broadinstitute.org/), and gnomAD (http://gnomad.broadinstitute.org/). Screening for the disease-causing variants (homozygous and compound heterozygous) led to the identification of a novel homozygous non-sense mutation (c.154C>T; p.Arg52*) in the exon 1 of MTHFR gene (NM_005957.4). Both the parents were heterozygous for the identified variant. The identified variant was absent in different available databases (dbSNP, 1000 genomes, ExAC, and gnomAD) and several in-house exomes (control).
In silico Analysis
Pathogenicity of the identified variant was evaluated with different online mutation prediction tools such as MutationTaster (mutationtaster.org), DNN (https://cbcl.ics.uci.edu/public_data/DANN/), FATHMM (fathmm.biocompute.org.uk), LRT (genetics.wustl.edu/jflab/lrt_query.html), VarSome (https://varsome.com/), CADD—Combined Annotation Dependent Depletion (https://cadd.gs.washington.edu/), and MutationAssessor (mutationassessor.org).
The identified variant (c.154C>T) was also subjected to Sanger sequencing with all the available members of the family using standard methods (Centogene, Germany), and the variant was shown to perfectly segregate with the disease phenotype.
Discussion and Conclusions
MTHFR (EC 1.5.1.20) is a key enzyme of the folate cycle involved in the catalysis of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for the remethylation of homocysteine to methionine. Methionine is subsequently metabolized to form S-adenosylmethionine. Thus, any disturbance in the pathway, either through the supply of cobalamin/folate or MTHFR deficiency, may cause accumulation of homocysteine, leading to altered patterns of methylation [(7–9); Supplementary Figure 1].
In the present study, we investigated a single affected individual (III-7) with MTHFR deficiency demonstrating severe features such as microcephaly, delayed growth, ophthalmic issues, non-obstructive hydrocephalus, elevated blood homocysteine level, and elevated plasma methionine levels. Features reported in the proband were similar to the previously reported cases (9–13). The affected individual had an early onset (<1 year) of the disease. It has been previously observed that the patients with early onset exhibit lesser residual enzyme activity than those with late onset (>1 year) (12). Residual enzyme activity was not tested in the present study. We performed WES for all the available members of the family (Figure 1A) and identified a homozygous non-sense mutation (c.154C>T; p.Arg52*) in MTHFR gene. The non-sense mutation (p.Arg52*) was located within the catalytic domain and most likely resulted in the complete loss of function of the MTHFR protein, either through non-sense-mediated mRNA decay or via the production of a truncated MTHFR protein.
MTHFR gene is located on chromosome 1p36.22, exhibits 11 exons, and encodes a 656 amino acid protein (NP_005948.3) (Figure 2A). MTHFR protein exists as a homodimer comprising two N-terminal catalytic domains with binding sites for NADPH, methylene-THF, and cofactor FAD-linked to the regulatory domain (C-terminus) (Figure 2B). The mutation (p.Arg52*) identified herein is highly conserved across different species (Figure 2C). The exact association between the position of mutation and clinical phenotypes is yet unknown, as a biallelic loss-of-function mutation in any part of the protein results in extreme enzyme deficiency. This phenomenon highlights the importance of the complete peptide for proper enzyme activity (14).
Figure 2
As per our knowledge, 132 mutations have been reported in MTHFR gene that may cause several disorders such as homocystinuria, anencephaly, tetralogy of Fallot with cleft lip/palate, MTHFR deficiency, acute aortic dissection, reduced enzyme activity, association with preeclampsia, increased erythrocyte folate, respiratory failure and hypotonia, coronary heart disease, Ehlers-Danlos syndrome IV, and Facial palsy (11, 13, 15–18). Clinical comparison of patients with non-sense mutations in MTHFR gene has been compiled in Supplementary Table 1. Only 84 different mutations have been described in the literature that cause severe MTHFR deficiency, including 52 missense mutations, 12 splice acceptor/donor site, 8 non-sense mutations, 7 small deletions, 2 small indels, 2 start loss, and 1 gross insertion (Table 1). The majority of the mutations causing severe MTHFR deficiency are reported in the catalytic domain (Figure 2B).
Table 1
| Disorder | Amino acid change | Nucleotide change | Mutation type | Exon/Intron | Domain | |
|---|---|---|---|---|---|---|
| 1 | MTHFR deficiency | Arg6* | c.16A>T | Non-sense | Exon 1 | Serine rich |
| 2 | MTHFR deficiency | Arg46Gln | c.137G>A | Missense | Exon 1 | Catalytic |
| 3 | MTHFR deficiency | Arg46Trp | c.136C>T | Missense | Exon 1 | Catalytic |
| 4 | MTHFR deficiency | Trp59Cys | c.177G>T | Missense | Exon 1 | Catalytic |
| 5 | MTHFR deficiency | Trp59Ser | c.176G>C | Missense | Exon 1 | Catalytic |
| 6 | MTHFR deficiency | Pro66Leu | c.197C>T | Missense | Exon 1 | Catalytic |
| 7 | MTHFR deficiency | Arg68Gly | c.202C>G | Missense | Exon 1 | Catalytic |
| 8 | MTHFR deficiency | Ser78* | c.233C>G | Non-sense | Exon 1 | Catalytic |
| 9 | MTHFR deficiency | Arg82Trp | c.244C>T | Missense | Exon 2 | Catalytic |
| 10 | MTHFR deficiency | Ala113Thr | c.337G>A | Missense | Exon 2 | Catalytic |
| 11 | MTHFR deficiency | Ala116Thr | c.346G>A | Missense | Exon 2 | Catalytic |
| 12 | MTHFR deficiency | His127Tyr | c.379C>T | Missense | Exon 2 | Catalytic |
| 13 | MTHFR deficiency | Thr129Asn | c.386C>A | Missense | Exon 2 | Catalytic |
| 14 | MTHFR deficiency | Thr139Met | c.416C>T | Missense | Exon 2 | Catalytic |
| 15 | MTHFR deficiency | Gln147Pro | c.440A>C | Missense | Exon 2 | Catalytic |
| 16 | MTHFR deficiency | Ala175Thr | c.523G>A | Missense | Exon 3 | Catalytic |
| 17 | MTHFR deficiency | His181Asp | c.541C>G | Missense | Exon3 | Catalytic |
| 18 | MTHFR deficiency | Arg183Gln | c.548G>A | Missense | Exon 3 | Catalytic |
| 19 | MTHFR deficiency | Cys193Tyr | c.578G>A | Missense | Exon 3 | Catalytic |
| 20 | MTHFR deficiency | Ala195Val | c.584C>T | Missense | Exon 3 | Catalytic |
| 21 | MTHFR deficiency | Gly196Asp | c.587G>A | Missense | Exon 3 | Catalytic |
| 22 | MTHFR deficiency | Pro202Thr | c.604C>A | Missense | Exon 4 | Catalytic |
| 23 | MTHFR deficiency | Ile225Leu | c.673A>C | Missense | Exon 4 | Catalytic |
| 24 | MTHFR deficiency | Ala233Gly | c.698C>G | Missense | Exon 4 | Catalytic |
| 25 | MTHFR deficiency | Val253Phe | c.757G>T | Missense | Exon 4 | Catalytic |
| 26 | MTHFR deficiency | Pro254Ser | c.760C>T | Missense | Exon 4 | Catalytic |
| 27 | MTHFR deficiency | Gly255Val | c.764G>T | Missense | Exon 4 | Catalytic |
| 28 | MTHFR deficiency | Ile256Asn | c.767T>A | Missense | Exon 4 | Catalytic |
| 29 | MTHFR deficiency | Phe257Val | c.769T>G | Missense | Exon 4 | Catalytic |
| 30 | MTHFR deficiency | Asn324Ser | c.971A>G | Missense | Exon 5 | Catalytic |
| 31 | MTHFR deficiency | Leu333Pro | c.998T>C | Missense | Exon 5 | Catalytic |
| 32 | MTHFR deficiency | Arg335His | c.1004G>A | Missense | Exon 5 | Catalytic |
| 33 | MTHFR deficiency | Trp339Gly | c.1015T>G | Missense | Exon 5 | Catalytic |
| 34 | MTHFR deficiency | Arg345Cys | c.1033C>T | Missense | Exon 5 | Catalytic |
| 35 | MTHFR deficiency | Pro348Ser | c.1042C>T | Missense | Exon 6 | Regulatory |
| 36 | MTHFR deficiency | His354Tyr | c.1060C>T | Missense | Exon 6 | Regulatory |
| 37 | MTHFR deficiency | Arg357His | c.1070G>A | Missense | Exon 6 | Regulatory |
| 38 | MTHFR deficiency | Arg358* | c.1072C>T | Non-sense | Exon 6 | Regulatory |
| 39 | MTHFR deficiency | Arg363His | c.1088G>A | Missense | Exon 6 | Regulatory |
| 40 | MTHFR deficiency | Lys372Glu | c.1114A>G | Missense | Exon 6 | Regulatory |
| 41 | MTHFR deficiency | Tyr374* | c.1122C>G | Non-sense | Exon 6 | Regulatory |
| 42 | MTHFR deficiency | Arg377His | c.1130G>A | Missense | Exon 6 | Regulatory |
| 43 | MTHFR deficiency | Trp381Arg | c.1141T>C | Missense | Exon 6 | Regulatory |
| 44 | MTHFR deficiency | Gly387Asp | c.1160G>A | Missense | Exon 6 | Regulatory |
| 45 | MTHFR deficiency | Trp421Ser | c.1262G>C | Missense | Exon 7 | Regulatory |
| 46 | MTHFR deficiency | Ser440Leu | c.1319C>T | Missense | Exon 7 | Regulatory |
| 47 | MTHFR deficiency | Glu470* | c.1408G>T | Non-sense | Exon 8 | Regulatory |
| 48 | MTHFR deficiency | Tyr506Asp | c.1516T>G | Missense | Exon 8 | Regulatory |
| 49 | MTHFR deficiency | Tyr512Cys | c.1535A>G | Missense | Exon 9 | Regulatory |
| 50 | MTHFR deficiency | Arg535Gln | c.1604G>A | Missense | Exon 9 | Regulatory |
| 51 | MTHFR deficiency | Arg535Trp | c.1603C>T | Missense | Exon 9 | Regulatory |
| 52 | MTHFR deficiency | Val536Phe | c.1606G>T | Missense | Exon 9 | Regulatory |
| 53 | MTHFR deficiency | Trp561* | c.1683G>A | Non-sense | Exon 10 | Regulatory |
| 54 | MTHFR deficiency | Arg567* | c.1699C>T | Non-sense | Exon 10 | Regulatory |
| 55 | MTHFR deficiency | Pro572Leu | c.1715C>T | Missense | Exon 10 | Regulatory |
| 56 | MTHFR deficiency | Val575Gly | c.1724T>G | Missense | Exon 10 | Regulatory |
| 57 | MTHFR deficiency | Met581Ile | c.1743G>A | Missense | Exon 10 | Regulatory |
| 58 | MTHFR deficiency | Lys584* | c.1750A>T | Non-sense | Exon 10 | Regulatory |
| 59 | MTHFR deficiency | Leu598Pro | c.1793T>C | Missense | Exon 11 | Regulatory |
| 60 | MTHFR deficiency | Leu628Pro | c.1883T>C | Missense | Exon 11 | Regulatory |
| 61 | MTHFR deficiency | *657Arg | c.1969T>C | Stop loss | Exon 11 | Regulatory |
| 62 | MTHFR deficiency | *657Ser | c.1970G>C | Stop loss | Exon 11 | Regulatory |
| 63 | MTHFR deficiency | – | c.236+1G>A | Splice | Intron 2 | Catalytic |
| 64 | MTHFR deficiency | – | c.474A>T | Splice | Exon 2 | Catalytic |
| 65 | MTHFR deficiency | – | c.781-2A>G | Splice | Intron 5 | Catalytic |
| 66 | MTHFR deficiency | – | c.781-1G>A | Splice | Intron 5 | Catalytic |
| 67 | MTHFR deficiency | – | c.780+1G>T | Splice | Intron 5 | Catalytic |
| 68 | MTHFR deficiency | – | c.1166G>A | Splice | Exon 6 | Catalytic |
| 69 | MTHFR deficiency | – | c.1166+1G>A | Splice | Intron 7 | Catalytic |
| 70 | MTHFR deficiency | – | c.1347+1G>A | Splice | Intron 8 | Regulatory |
| 71 | MTHFR deficiency | – | c.1530+2T>C | Splice | Intron 9 | Regulatory |
| 72 | MTHFR deficiency | – | c.1632+2T>G | Splice | Intron 10 | Regulatory |
| 73 | MTHFR deficiency | – | c.1753-18G>A | Splice | Intron 10 | Regulatory |
| 74 | MTHFR deficiency | – | c.1752+1G>T | Splice | Intron 11 | Regulatory |
| 75 | MTHFR deficiency | – | c.643_645delAAG | Small deletions | Exon 4 | |
| 76 | MTHFR deficiency | – | c.-40_-41delTC | Small deletions 5′UTR | Intron 1 | Serine rich |
| 77 | MTHFR deficiency | – | c.662delG | Small deletions | Exon 4 | Catalytic |
| 78 | MTHFR deficiency | – | c.677_679delTCA | Small deletions | Exon 4 | Catalytic |
| 79 | MTHFR deficiency | – | c.1167-2delA | Small deletions | Exon 7 | Regulatory |
| 80 | MTHFR deficiency | – | c.1593delG | Small deletions | Exon 9 | Regulatory |
| 81 | MTHFR deficiency | – | c.1539dupA | Small deletions | Exon 9 | Regulatory |
| 82 | MTHFR deficiency | – | c.446_447delGCinsTT | Small indels | Exon 2 | Catalytic |
| 83 | MTHFR deficiency | – | c.1797_1808delins12 | Small indels | Exon 11 | Regulatory |
| 84 | MTHFR deficiency | Leu89_Pro101dup | c.276_314dup | Gross insertions | Exon 2 | Catalytic |
Mutations reported in the MTHFR gene causing a severe 5-10-MTHFR deficiency.
Furthermore, MTHFR knockout mice showed a decrease in methionine level, methionine/homocysteine ratio, dimethylglycine level, and lipid deposition in proximal aorta along with changes in cerebellar pathology, reduced cerebellum, reduced cerebral cortex, and developmental issues (19–21). A therapeutic strategy employing biochemical methods is important to normalize methionine level and decrease the plasma levels of homocysteine. Treatment for severe MTHFR deficiency is heterogeneous, and different combination and dosage of drugs are prescribed depending on the severity of the disorder. High doses of betaine have been suggested for patients with severe MTHFR deficiency (22, 23). Vitamins B6 and B12 supplementation with folic acid is also significant in the conversion of homocysteine into methionine. In the present study, the proband was prescribed a combination of betaine, methionine, vitamin B12, and L-5-MTHF that improved the overall condition, as she became more active, alert, and oriented and survived as compared to her affected siblings. At present, the proband is 14 months old, shows no apnea or seizure; hydrocephalus is not progressive and developmentally she can roll over. However, she is unable to sit, crawl, or walk and functions as a 4–5 months old infant. Folic acid dosages in combination with folate/folinic acid, hydroxocobalamin, cyanocobalamin, riboflavin, and carnitine have also been previously prescribed to some patients that could partially reduce the clinical symptoms and biochemical abnormalities (5).
In conclusion, we identified a novel biallelic non-sense mutation in a single affected individual suffering from severe MTHFR deficiency. MTHFR deficiency is potentially treatable when properly diagnosed at early stages. Clinicians should be aware of the phenotypes related to early-late onset of the disease. Timely molecular diagnosis and treatment with high dose of methyl donors is critical for the survival of these patients. Identification of the pathogenic variants of MTHFR gene may extend the knowledge about the spectrum of mutations and highlight the proper genotype-phenotype correlation.
Statements
Ethics statement
The present study was approved by the Institutional Review Board (KAIMRC) and followed Helsinki protocols. Written informed consent was obtained from the parents of the participant for the research study, presentation of photographs/radiographs, and publication of this case report.
Author contributions
SM and MU drafted the manuscript, collected samples, clinical data, analyzed data, and performed experiments. MAla analyzed genomic data. MAla and MAlf edited the manuscript, while MAlf supervised the study.
Funding
This study is funded by King Abdullah International Medical Research Centre, Riyadh (Grant: RC11/46).
Acknowledgments
The authors thank the family for participating in this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00411/full#supplementary-material
References
1.
DugalićSPetronijevicMStefanovicAJeremicKPetronijevicSVSoldatovicIet al. The association between IUGR and maternal inherited thrombophilias: a case-control study. Medicine. (2018) 97:e12799. 10.1097/MD.0000000000012799
2.
XuJLiKZhouW. Relationship between genetic polymorphism of MTHFR C677T and lower extremities deep venous thrombosis. Hematology. (2019) 24:108–111. 10.1080/10245332.2018.1526440
3.
WilliamsKTSchalinskeKL. Homocysteine metabolism and its relation to health and disease. Biofactors. (2010) 36:19–24. 10.1002/biof.71
4.
LossosATeltshOMilmanTMeinerVRozenRLeclercDet al. Severe methylenetetrahydrofolate reductase deficiency: clinical clues to a potentially treatable cause of adult-onset hereditary spastic paraplegia. JAMA Neurol. (2014) 71:901–4. 10.1001/jamaneurol.2014.116
5.
HuemerMMulder-BleileRBurdaPFroeseDSSuormalaTZeevBB. Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency. J Inherit Metab Dis. (2016) 39:115–24. 10.1007/s10545-015-9860-6
6.
UmairMShahKAlhaddadBHaackTBGrafEStromTMet al. Exome sequencing revealed a splice site variant in the IQCE gene underlying post-axial polydactyly type A restricted to lower limb. Eur J Hum Genet. (2017) 25:960–5. 10.1038/ejhg.2017.83
7.
FowlerB. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med. (2005) 5:77–86. 10.1055/s-2005-872394
8.
WatkinsDRosenblattDS. Update and new concepts in vitamin responsive disorders of folate transport and metabolism. J Inherit Metab Dis. (2012) 35:665–70. 10.1007/s10545-011-9418-1
9.
RosenblattDSLue-ShingHArzoumanianALow-NangLMatiaszukN. Methylenetetrahydrofolate reductase (MR) deficiency: thermolability of residual MR activity, methionine synthase activity, and methylcobalamin levels in cultured fibroblasts. Biochem Med Metab Biol. (1992) 47:221–5.
10.
GoyettePSumnerJSMilosRDuncanAMRosenblattDSMatthewsRGet al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. (1994) 7:195–200. 10.1038/ng0694-195
11.
BurdaPSchaferASuormalaTRummelTBurerCHeubergerDet al. Insights into se- vere 5,10-methylenetetrahydrofolate reductase deficiency: molecular genetic and enzymatic characterization of 76 patients. Hum Mutat. (2015) 36:611–21. 10.1002/humu.22779
12.
FroeseDSHuemerMSuormalaTBurdaPCoelhoDGuéantJLet al. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. Hum Mutat. (2016) 37:427–38. 10.1002/humu.22970
13.
BurdaPSuormalaTHeubergerDSchäferAFowlerBFroeseDSet al. Functional characterization of missense mutations in severe methylenetetrahydrofolate reductase deficiency using a human expression system. J Inherit Metab Dis. (2017) 40:297–306. 10.1007/s10545-016-9987-0
14.
LeclercDRozenR. [Molecular genetics of MTHFR: polymorphisms are not all benign]. Med Sci. (2007) 23:297–302. 10.1051/medsci/2007233297
15.
RummelTSuormalaTHäberleJKochHGBerningCPerrettDet al. Intermediate hyperhomocysteinaemia and compound heterozygosity for the common variant c.677C>T and a MTHFR gene mutation. J Inherit Metab Dis. (2007) 30:401. 10.1007/s10545-007-0445-x
16.
DohleCBaehringJM. Multiple strokes and bilateral carotid dissections: a fulminant case of newly diagnosed Ehlers-Danlos syndrome type IV. J Neurol Sci. (2012) 318:168–70. 10.1016/j.jns.2012.04.005
17.
LiuLBuHYangYTanZZhangFHuSet al. A Targeted, next-generation genetic sequencing study on tetralogy of fallot, combined with cleft lip and palate. J Craniofac Surg. (2017) 28:e351–5. 10.1097/SCS.0000000000003598
18.
IshidaMCullupTBoustredCJamesCDockerJEnglishCet al. A targeted sequencing panel identifies rare damaging variants in multiple genes in the cranial neural tube defect, anencephaly. Clin Genet. (2018) 93:870–9. 10.1111/cge.13189
19.
ChenZKaraplisACAckermanSLPogribnyIPMelnykSet al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. (2001) 10:433–44. 10.1093/hmg/10.5.433
20.
SchwahnBCChenZLaryeaMDWendelULussier-CacanSGenestJJret al. Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. (2003) 17:512–4. 10.1096/fj.02-0456fje
21.
ChenZSchwahnBCWuQHeXRozenR. Postnatal cerebellar defects in mice deficient in methylenetetrahydrofolate reductase. Int J Dev Neurosci. (2005) 23:465–74. 10.1016/j.ijdevneu.2005.05.007
22.
StraussKAMortonDHPuffenbergerEGHendricksonCRobinsonDLWagnerCet al. Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. (2007) 91:165–75. 10.1016/j.ymgme.2007.02.012
23.
IidaSNakamuraMAsayamaSKuniedaTKanekoSOsakaHet al. Rapidly progressive psychotic symptoms triggered by infection in a patient with methylenetetrahydrofolate reductase deficiency: a case report. BMC Neurol. (2017) 17:47. 10.1186/s12883-017-0827-0
Summary
Keywords
MTHFR, non-sense mutation, white matter disease, microcephaly, severe methylenetetrahydrofolate reductase deficiency
Citation
Massadeh S, Umair M, Alaamery M and Alfadhel M (2019) A Novel Homozygous Non-sense Mutation in the Catalytic Domain of MTHFR Causes Severe 5,10-Methylenetetrahydrofolate Reductase Deficiency. Front. Neurol. 10:411. doi: 10.3389/fneur.2019.00411
Received
06 February 2019
Accepted
04 April 2019
Published
24 April 2019
Volume
10 - 2019
Edited by
Ignacio Mata, Cleveland Clinic, United States
Reviewed by
Luca Marsili, University of Cincinnati, United States; Oriol Dols-Icardo, Sant Pau Institute for Biomedical Research, Spain
Updates
Copyright
© 2019 Massadeh, Umair, Alaamery and Alfadhel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Majid Alfadhel dralfadhelm@gmail.com
This article was submitted to Neurogenetics, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.